Table 1.
Description of Women Included in the Analysis Initiating Tenofovir, Emtricitabine, and Efavirenz During Pregnancy and Achieving Viral Suppression—Cape Town, South Africa
| Characteristic | No. (%) |
|---|---|
| No. | 523 (100) |
| Age, y, median (IQR) | 28 (24–32) |
| Parity: nulliparous | 100 (19) |
| Gestation at ART initiation, wk | |
| Median | 21 |
| ≤14 | 82 (16) |
| >14–28 | 330 (63) |
| >28 | 111 (21) |
| Previous antiretroviral exposure | |
| None | 374 (72) |
| NVP only | 6 (1) |
| ZDV + NVP | 121 (23) |
| Triple-drug therapy | 18 (3) |
| Pre-ART CD4 count, cells/µL | |
| Median | 345 |
| <200 | 83 (16) |
| 200–350 | 177 (34) |
| 350–500 | 116 (22) |
| >500 | 147 (28) |
| Pre-ART VL, log10 copies/mL | |
| Median | 3.99 |
| <3.0 | 72 (14) |
| 3.0–4.0 | 194 (37) |
| 4.0–5.0 | 206 (39) |
| >5.0 | 51 (10) |
| Time from ART initiation to VL suppression, d, median (IQR) | 91 (28–130) |
| Time of follow-up from suppression, d, median (IQR) | 322 (141–410) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ART, antiretroviral therapy; IQR, interquartile range; NVP, nevirapine; VL, viral load; ZDV, zidovudine.